Morgan Stanley analysts Sean Laaman and Maxwell Skor have flagged Alzheimer's drugs, gene editing and artificial intelligence as the three biotech breakthroughs most likely to reward investors, in research published around the bank's annual Global Healthcare Conference in New York.
The call splits the sector into near-term commercial opportunities and longer-dated platform bets, with the analysts favoring companies that sell into the boom over those that might be transformed by it.
A $70 billion Alzheimer's market, and who gets paid
Morgan Stanley puts the Alzheimer's opportunity at $70 billion, dividing it between therapies that slow cognitive decline and treatments for symptoms such as psychosis and agitation. The analysts see the wider value spilling into diagnostics, care delivery, retirement and insurance businesses if the drugs delay nursing home entry by 12 to 18 months — a saving, they argue, worth multiples of list price to the US healthcare system.
That framing matters because it's the kind of outcome payers notice. A drug that keeps patients at home for a year or more changes the math for insurers and government programs in a way that a modest cognitive improvement doesn't.
Gene editing moves inside the body
The gene-editing story has shifted from ex vivo work, where cells are removed, edited in a lab and returned, to in-vivo treatments that edit DNA directly inside the body. That opens organs that can't easily be taken out — the brain, heart, eyes and liver among them.
Morgan Stanley forecasts a $10 billion in-vivo gene-editing market by 2035 across near-term indications, well above the $6 billion consensus. Clinical data expected over the next 18 months should go a long way to settling which number is right, and the readouts will shape how investors value the platforms behind them.
AI's productivity promise is real but unproven
On artificial intelligence, the bank estimates the technology could cut drug discovery timelines from roughly 4.5 years to 1.5 years and reduce research and development costs by 25% to 60%. The catch: there's little evidence yet that AI raises the odds of a drug actually reaching patients.
That gap explains why Morgan Stanley prefers AI suppliers — the companies providing data, tools and computing power — over drug developers. Suppliers already convert adoption into revenue and aren't hostage to binary clinical outcomes. The bank watches some AI-focused biotechs selectively for clinical inflection points, but takes a skeptical view of large-cap productivity gains.
Why single readouts still move the tape
Clinical data can swing biotech shares hard, as Moderna's rally in August after a late-stage cancer vaccine result demonstrated. Morgan Stanley strategist Mike Wilson warned in mid-September of a correction within 30 days if an oil spike drains liquidity, a reminder that sector momentum can be derailed by macro forces.
Pharma and biotech performance has been climbing since mid-2025, but the bank's stock calls rest on a split view: own the picks-and-shovels names, and treat platform promises with caution until the data lands.
The next 18 months of gene-editing readouts — along with any Alzheimer's and AI clinical updates — will test whether the analysts' $10 billion in-vivo forecast holds up or gives way to consensus.
